Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank

The Russell 2000 has rallied to about +16% YTD and could be the second-best U.S. index into late 2025, a move Zacks attributes to the Fed’s latest 25bp easing to a 3.50–3.75% fed funds range and the seasonally strong mid‑December to early‑March window for small caps. Zacks spotlights several speculative, high‑flyers: Celcuity (CELC) is up roughly +695% (market cap $4.71bn) but remains unprofitable with FY25 EPS est. −$3.86 and a Zacks Rank #3 (Hold); Better Home & Finance (BETR) is +442% (mkt cap ~$795m) with rapid sales growth yet a Zacks Rank #4 (Sell) and EPS revisions drifting lower despite revenue projections rising to $273m next year; Cogent Biosciences (COGT) is +413% (mkt cap $5.58bn), advancing clinically with a potential 2026 FDA filing for bezuclastinib but still pre‑commercial and forecast to post a narrower adjusted loss of −$1.77 in FY26 (Zacks Rank #3). Zacks’ takeaway: gains are largely momentum‑driven and idiosyncratic, warranting monitoring of EPS revisions and clinical/earnings catalysts, with IWM (iShares Russell 2000) presented as a diversified Zacks Rank #2 (Buy) alternative.

Analysis

The Federal Reserve's 25 basis-point cut to a 3.50–3.75% fed funds range and seasonal strength for small caps (mid‑December to early March) are cited as primary drivers behind the Russell 2000's roughly +16% year‑to‑date performance and the current surge into speculative small‑cap names. Lower rates improve financing conditions for small businesses and, combined with portfolio rebalancing, have amplified risk appetite into late 2025.

Zacks highlights three extreme YTD performers: Celcuity (CELC) at $100 (+~695% YTD, market cap $4.71bn) carries a Zacks Rank #3 with FY25 EPS est. −$3.86 and FY26 −$4.05 despite recent positive revisions; Better Home & Finance (BETR) at $48 (+442%, mkt cap ~$795m) shows >50% projected revenue growth but a Zacks Rank #4 and near‑term EPS revisions turning down; Cogent (COGT) at $40 (+413%, mkt cap $5.58bn) is pre‑commercial, targeting a 2026 FDA filing and is expected to narrow adjusted loss to −$1.77 in FY26 (Zacks Rank #3).

The pattern is momentum and idiosyncratic gains rather than improved fundamentals across the board: valuations and lack of profitability raise reversal risk, and future performance hinges on catalysts (clinical readouts, FDA filings, and EPS revision trends). For investors seeking exposure with lower single‑name risk, Zacks points to IWM (iShares Russell 2000) as a diversified alternative with a Zacks Rank #2 (Buy).

Key Decisions for Investors

• Consider using IWM for broad Russell 2000 exposure rather than concentrated stakes in highly speculative winners, given IWM's Zacks Rank #2 and the index's +16% YTD performance
• Trim or take profits in extreme momentum names like CELC, BETR and COGT where valuations appear stretched and underlying EPS remain negative or uncertain
• If retaining biotech or fintech winners, size positions conservatively and monitor EPS revisions and specific catalysts (e.g., Cogent's planned 2026 FDA filing) before adding
• Use protective hedges or options to lock gains during the seasonally strong window while remaining prepared to redeploy into better entry points that Zacks suggests may arrive later